Medalytix

Medalytix develops and markets products which automatically detect signs of disease by scanning digital photographs of the eye.

Its flagship product, iGradingM, automatically detects diabetic retinopathy, the most common cause of working age blindness.  In manually operated retinal screening services each image is currently assessed an average of twice by highly‐skilled technical individuals, making it a time consuming, expensive and tedious task to consistently and accurately analyse each picture. iGradingM directly addresses these issues by automating the bulk of the manual work, using a safe and consistent system to identify retinal images with signs of disease.

 A substantial publication base supports the system which has demonstrable clinical effectiveness and safety within live screening programmes. A recent clinical study compared the output of the system to the manual results in a National Screening Programme in the UK and showed 100% sensitivity to actionable retinopathy (Fleming et al, BJO 2010). Peer-reviewed papers in support of the core algorithms within iGradingM are highlighted in the Download section.

iGradingM is a proven solution for automated level 1 “disease/no disease” grading and following a successful audit phase, the first national deployment is underway within the Scottish National Diabetic Retinopathy Screening Programme in a patient community of almost 200,000. iGradingM can be seamlessly integrated with existing patient management systems, allowing healthcare providers to easily introduce demonstrated cost-saving measures for the benefit of their patients and the wider community.

The team at Medalytix are experts in the delivery of effective diabetic retinopathy screening programmes and we can also provide tailor-made consulting services on retinal screening. Please contact us if you are intending to implement a new screening programme and would like support (info@medalytix.com)

Further developments, including cardiovascular disease (CVD) risk prediction and detection of age related macular degeneration (AMD), are in the pipeline. The disease areas addressed by Medalytix concern long-term conditions affecting large populations and incurring significant cost to healthcare systems.  The product portfolio addresses the following areas:

• Automated detection of diabetic retinopathy;
• Non-invasive screening for cardiovascular disease risk;
• Automated detection of AMD;
• Novel, objective, automated measurement approaches for use in patient monitoring and  drug therapy trials

         -  Objective assessment of early stage neuropathy via automated assessment of small fibre neuropathy in the cornea;

         -  Objective, quantitative assessment of fundal fluorescein angiograms

• Privacy Policy
• Legal